The abstract is read at the publisher; the summary is JClub's.
Intravenous bisphosphonate use is linked to increased short-term uveitis risk in Taiwan claims data (OR 1.24; 95% CI 1.00–1.56), especially anterior uveitis.
- Why it matters: The study addresses uncertainty about whether bisphosphonates are associated with acute ocular inflammatory events shortly after exposure, and which routes or agents may matter.
- What they did: Using a nationwide case-case-time-control design in Taiwan (2011–2021), incident uveitis, scleritis, and CME cases were compared across a 30-day hazard window versus an earlier 30-day reference window with a 90-day washout, matched to future cases.
- The result: Intravenous bisphosphonates showed higher uveitis odds (OR 1.78; 95% CI 1.22–2.61), particularly zoledronic acid (OR 2.82; 95% CI 1.70–4.67), while oral bisphosphonates were not associated (OR 0.99; 95% CI 0.74–1.33); scleritis and CME had no clear associations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.